About Homie

Homie Razavi is the founder and managing director at the Center for Disease Analysis (CDA), an organization specializing in studying complex and poorly understood diseases. CDA’s goal is to study and publish data to help educate stakeholders and support decision-making in different countries.

Since 2008, Homie has led a team of epidemiologists and modellers to quantify epidemiology of hepatitis C virus (HCV) and forecast the future impact of HCV disease burden. They have analyzed HCV disease burden in over seventy countries and have helped countries develop national strategies. CDA has been responsible for the development of a number of mathematical models currently used by countries to develop intervention strategies for HCV and HBV:
HCV disease progression
HCV transmission
HCV economic impact
HBV vertical transmission; economic impact
HBV disease progression/treatment; economic impact

In addition, CDA has developed the Polaris Observatory, which collects and reports HCV, HBV and HDV epidemiology, disease burden and treatment rate annually. He has a broad background, which includes basic research, commercial development, portfolio management, and decision analysis. He is also a fellow in the Society of Decision Professionals.

This speaker will be presenting at the following session(s)

  • Strategic direction 4: financing for sustainability

    Golden Hall

    Day: 3 November

    Time: 09:00

    The first of two plenary sessions on strategic direction 4, which addresses the sustainable financing of hepatitis responses within a whole health systems approach.

    Chairs: Dr. Amanda Kgomotso Vilakazi Nhlapo, National Department of Health, South Africa

    Presentations:

    • A strategic approach to financing hepatitis.
      Charles Gore, World Hepatitis Alliance
    • Costing, delivery and financing for hepatitis – the linkages.
      Dr. Jeremy Lauer, World Health Organization
    • Panel discussion: financing for hepatitis within a health systems approach.
      Moderator: Dr. Eduardo González Pier
      Dr. David Wilson, World Bank
      Dr. Jean Damascene Makuza, Rwanda Biomedical Center
      Dr. Jeremy Lauer, World Health Organization
      Dr. Homie Razavi, Center for Disease Analysis

    Session objective:

    • Discover how to approach hepatitis costing, budgeting and financing in a structured way.
    • Understand how the financing system must match the service delivery model and where there are opportunities for integration.
    • Learn how countries can best approach sustainable financing for hepatitis.
  • Strategic direction 4: different financing mechanisms for viral hepatitis programmes

    Golden Hall

    Day: 3 November

    Time: 11:00

    This session examines potential hepatitis financing mechanisms that will be required for countries to launch, accelerate and sustain public health responses to viral hepatitis.

    Chairs: Dr Adele Benzaken, Ministry of Health, Brazil

    Presentations:

    • From economic analysis to financial dialogue.
      Dr. Homie Razavi, Center for Disease Analysis
    • A new Fund for Elimination of Viral Hepatitis: EndHEP2030.
      Wangsheng Li, Zeshan Foundation
    • Getting started with funding: catalytic initiatives.
      Taryn Barker, Clinton Health Access Initiative
    • Engaging Ministries of Finance.
      Eduardo González-Pier, Center for Global Development
    • Domestic funding.
    • Q & A session.

    Session objectives:

    • Understand the global investment case and its use in attracting donors.
    • Learn how to ensure the support of Ministries of Finance.
    • Understand how the public and private sector can be combined.
    • Discover how 3 countries have approached hepatitis financing.